Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase

作者: William J. Suling , Lainne E. Seitz , Vibha Pathak , Louise Westbrook , Esther W. Barrow

DOI: 10.1128/AAC.44.10.2784-2793.2000

关键词:

摘要: Development of new antimycobacterial agents for Mycobacterium avium complex (MAC) infections is important particularly persons coinfected with human immunodeficiency virus. The objectives this study were to evaluate the in vitro activity 2,4-diamino-5-methyl-5-deazapteridines (DMDPs) against MAC and assess their activities dihydrofolate reductase recombinant enzyme (rDHFR). Seventy-seven DMDP derivatives evaluated initially one three strains (NJ168, NJ211, and/or NJ3404). MICs determined 10-fold dilutions drug a colorimetric (Alamar Blue) microdilution broth assay. rDHFR 50% inhibitory concentrations versus those also determined. Substitutions at position 5 pteridine moiety included -CH 3 , 2 CH OCH groups. Additionally, different substituted unsubstituted aryl groups linked 6 through two-atom bridge either NH, N(CH ), or S. All but 4 77 active NJ168 ≤13 μg/ml. Depending on strain used, 81 87% had ≤1.3 Twenty-one >100-fold more than rDHFR. In general, selectivity was dependent composition attached group substitutions 2′ 5′ positions phenyl ring. Using assessment, rational synthetic approach implemented that resulted derivative significant intracellular MAC-infected Mono Mac monocytic cell line. These results demonstrate it possible synthesize have selective MAC.

参考文章(36)
Anil K. Saxena, Mridula Saxena, Advances in chemotherapy of malaria. Progress in drug research. ,vol. 30, pp. 221- 280 ,(1986) , 10.1007/978-3-0348-9311-4_8
Erika Bruck, National Committee for Clinical Laboratory Standards. Pediatrics. ,vol. 65, pp. 187- 188 ,(1980)
Carolyn M. Shoen, Olga Choromanska, Robert C. Reynolds, James R. Piper, Cheryl A. Johnson, Michael H. Cynamon, In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 3315- 3316 ,(1998) , 10.1128/AAC.42.12.3315
Barry I. Schweitzer, Adam P. Dicker, Joseph R. Bertino, Dihydrofolate reductase as a therapeutic target The FASEB Journal. ,vol. 4, pp. 2441- 2452 ,(1990) , 10.1096/FASEBJ.4.8.2185970
E L Wright, D C Quenelle, W J Suling, W W Barrow, Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 2206- 2208 ,(1996) , 10.1128/AAC.40.9.2206
S ZYWNOVANGINKEL, T DOOLEY, W SULING, W BARROW, Identification and cloning of the A gene, required for dihydrofolate reductase activity Fems Microbiology Letters. ,vol. 156, pp. 69- 78 ,(1997) , 10.1016/S0378-1097(97)00402-3
Aleem Gangjee, Anil Vasudevan, Sherry F. Queener, Roy L. Kisliuk, 2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases Journal of Medicinal Chemistry. ,vol. 39, pp. 1438- 1446 ,(1996) , 10.1021/JM950786P
Sabrina Zywno-van Ginkel, Thomas P Dooley, William J Suling, William W Barrow, Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity Fems Microbiology Letters. ,vol. 156, pp. 69- 78 ,(2006) , 10.1111/J.1574-6968.1997.TB12707.X
J.H. Schornagel, J.G. McVie, The clinical pharmacology of methotrexate Cancer Treatment Reviews. ,vol. 10, pp. 53- 75 ,(1983) , 10.1016/S0305-7372(83)80032-2
Gert Riethmüller, H. W. Löms Ziegler-Heitbroc, Eckhard Thiel, Agnes Futterer, Volker Herzog, Antje Wirtz, Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes International Journal of Cancer. ,vol. 41, pp. 456- 461 ,(1988) , 10.1002/IJC.2910410324